Thermo Fisher: Modest Q2 for life sciences due to ‘lumpiness’ of bioproduction

By Dan Stanton contact

- Last updated on GMT

Image: iStock/tadamichi
Image: iStock/tadamichi

Related tags: Thermo fisher, Thermo fisher scientific, Thermo electron

Muted bioproduction technology pegged back an otherwise strong quarter, but Thermo Fisher says it expects growth will pick up again over time.

For the second quarter 2017, Thermo Fisher Scientific reported revenue of $5bn and profits of $612m, up 10% and 12% year-on-year.

But after a number of quarters of double-digit and high single-digit growth, its life sciences business grew just 3% to $1.4bn compared with the same period last year.

This was attributed to muted growth in its bioproduction business – consisting of bioprocessing cell culture and cell harvesting systems, and accompanying containers and consumables – which according to CEO Marc Casper is a trend seen across the industry.

“There's some lumpiness. In Q2, while it grew reasonably, it was softer than the very torrid growth that we had the last few quarters, and we would expect that growth will pick up over time there. So that's our view on bioproduction,” ​he said on a conference call to discuss results.

His view mirrors that of rival Sartorius Stedim Biotech (SSB)​ which said it too had seen modest sales growth across its bioprocessing division in Q2 due to the robustness of previous years.

Casper told investors he was confident growth would pick up again.

“Bioproduction is definitely a lumpy business, and the long-term prospect for bioproduction is fantastic. When you think about the demand for biologics, biosimilars, vaccines in the pipeline, we are very bullish.

"One of the leading indicators we have is our biosciences business serves the research customer base with those technologies, especially media and sera, and that business is incredibly robust, so the activity level is very strong."

Patheon acquisition

Casper also spoke about Thermo Fisher’s proposed $7.2bn acquisition of contract development and manufacturing organisation (CDMO) Patheon, announced in May​.

“We're really excited about the new outsourcing services we'll gain from Patheon, which will allow us to provide comprehensive support for our biopharma customers, from drug development to clinical trials to commercial manufacturing,”​ Casper said.

He added: “We're very confident in our ability to close by the end of the year, and look forward to officially welcoming our new Patheon colleagues to thermos Fisher.”

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more